<DOC>
	<DOCNO>NCT01643382</DOCNO>
	<brief_summary>Based multiple prior study , kidney transplant recipient diabetes high risk poor initial graft function transplant . Our study design determine tight blood sugar control around time kidney transplant improve short term graft function .</brief_summary>
	<brief_title>Hyperglycemia Renal Transplantation</brief_title>
	<detailed_description>Population- Our study population include adult diabetic patient undergo deceased donor renal transplantation live donor transplantation swap require transportation result cold storage time . This ensure reasonable incidence primary outcome ( poor short term graft function ) eliminate potential risk treat non-diabetic patient insulin infusion . Patients already enrol drug trial design study impact drug graft function exclude . Study Design- This randomize control trial . Recipients randomize either tight peri-operative glucose control standard management . Methods Randomization Protocol- In order ensure patient equally distributed group , use block randomization . Blocks 4 patient create total number experimental versus control assignments equal across block . Patients randomly assign block . Interventions- The study group treat insulin infusion achieve tight glycemic control ( 100-140mg/dL ) . Each study patient start insulin infusion prior operation . This infusion continue throughout operation 24 hour completion transplant . Glucose control leave discretion primary team . The control group treat bolus insulin base standard insulin slide scale . Outcomes Aim 1- Primary endpoint- Our primary endpoint poor initial graft function define occurrence DGF ( define decrease serum creatinine &lt; 10 % /day 3 consecutive day transplant ) slow graft function ( serum creatinine &gt; 3 mg/dL 5 day transplant without dialysis ) Secondary endpoint- Secondary endpoint include wound infection , length hospital stay , 30 day mortality , hypoglycemic episode ( glucose &lt; 70 mg/dL ) stroke . Aim 2- Primary endpoint- Our primary endpoint acute rejection 90 day graft survival/renal function 3months , 6months yearly . Statistical Analysis- Data describe mean standard deviation percentage range base whether data represent continuous categorical variable . The t-test chi-squared test use test hypothesis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>adult patient diabetic end stage renal disease undergo cadaveric renal transplant enrol concurrent study test impact drug graft function transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>delay draft function</keyword>
</DOC>